The genetic determinants of the CYP3A5 polymorphism

被引:568
作者
Hustert, E
Haberl, M
Burk, O
Wolbold, R
He, YQ
Klein, K
Nuessler, AC
Neuhaus, P
Klattig, J
Eiselt, R
Koch, I
Zibat, A
Brockmöller, J
Halpert, JR
Zanger, UM
Wojnowski, L
机构
[1] Epidauros Biotechnol AG, Bernried, Germany
[2] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-7000 Stuttgart, Germany
[3] Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77550 USA
[4] Humboldt Univ, Univ Med Ctr Charite, Dept Surg, Berlin, Germany
[5] Humboldt Univ, Univ Med Ctr Charite, Inst Clin Pharmacol, Berlin, Germany
来源
PHARMACOGENETICS | 2001年 / 11卷 / 09期
关键词
CYP3A5; CYP3A4; polymorphism; drug metabolism;
D O I
10.1097/00008571-200112000-00005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
CYP3A proteins comprise a significant portion of the hepatic cytochrome P450 (CYP) protein and they metabolize aroud 50% of drugs currently in use. The dissection of the individual contributions of the four CYP3A genes identified in humans to overall hepatic CYP3A activity has been hampered by sequence and functional similarities. We have investigated the expression of CYP3A5 and its genetic determinants in a panel of 183 Caucasian liver samples. CYP3A5 expression is increased in 10% of livers in this ethnic group. Using a high density map of CYP3A5 variants, we searched for genetic markers of the increased CYP3A5 expression. In agreement with an independent, recent study, we report that a SNIP within intron 3 (g.6986G>A) is the primary cause of the CYP3A5 protein polymorphism. The frequencies of the g.6986A variant which allow for normal splicing of CYP3A5 transcripts are 5% in Caucasians, 29% in Japanese, 27% in Chinese, 30% in Koreans and 73% in African-Americans. In the last ethnic group, the expression of CYP3A5 in some individuals who carry the g.6986A variant is affected adversely by a frame shift mutation (CYP3A5*7, D348., q=0.10). In summary, these results should add to efforts to identify clinically relevant, CYP3A5-specific reactions and to further elucidate traits responsible for variable expression of the entire CYP3A family. Pharmacogenetics 11:773-779 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:773 / 779
页数:7
相关论文
共 26 条
[1]  
Antonarakis SE, 1998, HUM MUTAT, V11, P1
[2]  
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[3]   Dissecting the function of cytochrome P450 [J].
Boobis, AR ;
Edwards, RJ ;
Adams, DA ;
Davies, DS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (01) :81-89
[5]  
DEWAZIERS I, 1990, J PHARMACOL EXP THER, V253, P387
[6]   cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome p450 [J].
Domanski, TL ;
Finta, C ;
Halpert, JR ;
Zaphiropoulos, PG .
MOLECULAR PHARMACOLOGY, 2001, 59 (02) :386-392
[7]   Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity [J].
Domanski, TL ;
He, YA ;
Khan, KK ;
Roussel, F ;
Wang, QM ;
Halpert, JR .
BIOCHEMISTRY, 2001, 40 (34) :10150-10160
[8]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[9]   Genomic organization of the human CYP3A locus:: identification of a new, inducible CYP3A gene [J].
Gellner, K ;
Eiselt, R ;
Hustert, E ;
Arnold, H ;
Koch, I ;
Haberl, M ;
Deglmann, CJ ;
Burk, O ;
Buntefuss, D ;
Escher, S ;
Bishop, C ;
Koebe, HG ;
Brinkmann, U ;
Klenk, HP ;
Kleine, K ;
Meyer, UA ;
Wojnowski, L .
PHARMACOGENETICS, 2001, 11 (02) :111-121
[10]   EXPRESSION OF CYTOCHROME-P450-3A5 IN ESCHERICHIA-COLI - EFFECTS OF 5' MODIFICATION, PURIFICATION, SPECTRAL CHARACTERIZATION, RECONSTITUTION CONDITIONS, AND CATALYTIC ACTIVITIES [J].
GILLAM, EMJ ;
GUO, ZY ;
UENG, YF ;
YAMAZAKI, H ;
COCK, I ;
REILLY, PEB ;
HOOPER, WD ;
GUENGERICH, FP .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 317 (02) :374-384